Get the Stockscreener App
0.9335
3.07%
-0.0296
After Hours:
.93
-0.0035
-0.37%
iBio Inc stock is traded at $0.9335, with a volume of 471.90K.
It is down -3.07% in the last 24 hours and up +62.89% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$0.9631
Open:
$0.93
24h Volume:
471.90K
Relative Volume:
0.21
Market Cap:
$18.35M
Revenue:
$2.05M
Net Income/Loss:
$-23.15M
P/E Ratio:
-0.1408
EPS:
-6.6319
Net Cash Flow:
$-16.93M
1W Performance:
+11.80%
1M Performance:
+62.89%
6M Performance:
-83.18%
1Y Performance:
-50.92%
1-Day Range:
$0.92
$0.9595
1-Week Range:
$0.82
$0.9691
52-Week Range:
$0.5562
$6.8908
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
0.9335 | 17.35M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
iBio Inc Stock (IBIO) Latest News
What machine learning models say about iBio Inc.July 2025 PostEarnings & Precise Buy Zone Identification - Newser
Is iBio Inc. still worth holding after the dipJuly 2025 Reactions & Accurate Buy Signal Alerts - Newser
What’s the recovery path for long term holders of iBio Inc.2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - Newser
Best data tools to analyze iBio Inc. stockMarket Risk Report & Free Low Drawdown Momentum Trade Ideas - Newser
Sector ETF performance correlation with iBio Inc.GDP Growth & Safe Capital Growth Plans - Newser
Does iBio Inc. fit your quant trading modelJuly 2025 Fed Impact & AI Optimized Trading Strategy Guides - Newser
Multi asset correlation models including iBio Inc.2025 Momentum Check & Safe Capital Preservation Plans - Newser
Big Picture: How cyclical is iBio Inc.’s revenue streamAnalyst Upgrade & Weekly Momentum Picks - Lancaster City Council
Is a relief rally coming for iBio Inc. holdersWeekly Profit Report & Technical Buy Zone Confirmations - Newser
iBio Full Year 2025 Earnings: US$1.75 loss per share (vs US$4.03 loss in FY 2024) - Yahoo Finance
What hedge funds are buying iBio Inc.July 2025 Levels & Fast Gain Swing Trade Alerts - خودرو بانک
Can iBio Inc. be recession proofEarnings Overview Report & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Ibio Inc’s Future at Risk: Reliance on Third-Party Licenses for Key Product Candidates - TipRanks
iBio, Inc. Reports Transformative Fiscal Year 2025 - TipRanks
Brookline Capital Markets reiterates Buy rating on iBio stock with $1.60 target - Investing.com India
What MACD and RSI say about iBio Inc.Market Sentiment Review & Entry Point Confirmation Signals - Newser
Brookline Capital Markets reiterates Buy rating on iBio stock with $1.60 target By Investing.com - Investing.com South Africa
Why is iBio Inc. stock going upJuly 2025 Update & Risk Controlled Swing Trade Alerts - خودرو بانک
Is iBio Inc. trending in predictive chart modelsWeekly Trade Report & AI Enhanced Trade Execution Alerts - Newser
IBio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2025 - MarketScreener
iBio, Inc. SEC 10-K Report - TradingView
iBio (IBIO) Reports Revenue Growth and Strategic Advancements - GuruFocus
iBio Sets Sights on Clinic for Treatments of Obesity, Heart Disease - San Diego Business Journal
iBio Reports Fiscal Year 2025 Financial Results and Provides Cor - GuruFocus
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - The Manila Times
IBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - MarketScreener
26% Fat Loss Without Muscle Loss: iBio's New Obesity Drug IBIO-610 Shows Promise in Preclinical Data - Stock Titan
Multi factor analysis applied to iBio Inc.Market Risk Report & Free High Accuracy Swing Entry Alerts - Newser
Volatility clustering patterns for iBio Inc.Weekly Trade Analysis & Risk Controlled Daily Trade Plans - Newser
Is iBio Inc. undervalued by DCF analysisInsider Selling & Entry Point Strategy Guides - خودرو بانک
What’s the analyst consensus on iBio Inc.Weekly Stock Recap & Growth Focused Investment Plans - خودرو بانک
What earnings revisions data tells us about iBio Inc.Weekly Trade Report & AI Enhanced Trade Execution Alerts - Newser
Is now a turning point for iBio Inc.July 2025 News Drivers & Expert Approved Momentum Trade Ideas - Newser
Backtesting results for iBio Inc. trading strategiesJuly 2025 Technicals & Long-Term Safe Investment Ideas - Newser
Can technical indicators confirm iBio Inc.’s reversal2025 Technical Patterns & Long-Term Safe Investment Plans - Newser
Volume spikes in iBio Inc. stock – what they mean2025 Performance Recap & Consistent Income Trade Ideas - Newser
Using portfolio simulators with iBio Inc. includedEarnings Risk Report & Consistent Growth Equity Picks - Newser
What’s next for iBio Inc. stock priceWeekly Market Report & Precise Entry and Exit Recommendations - Newser
Is iBio Inc. forming a reversal patternJuly 2025 Sentiment & Expert Verified Movement Alerts - Newser
iBio Inc. stock daily chart insights2025 Momentum Check & Reliable Entry Point Trade Alerts - Newser
iBio Inc. stock chart pattern explained2025 Trading Recap & AI Forecast for Swing Trade Picks - Newser
Can iBio Inc. expand its profit marginsEarnings Overview Report & Daily Stock Trend Watchlist - خودرو بانک
How to escape a deep drawdown in iBio Inc.Analyst Upgrade & Advanced Swing Trade Entry Plans - Newser
Can you recover from losses in iBio Inc.Breakout Watch & AI Based Buy/Sell Signal Reports - Newser
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):